Drug Trial Radar · NCT04614740
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
115
Planned (sponsor's estimate)
Start
Nov 20, 2020
Primary completion
Jan 31, 2024
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dose-escalation study will be conducted in patients with locally advanced/metastatic solid tumors who have failed standard treatment, or cannot tolerate standard treatment, or have no recommended standard treatment, or do not apply standard treatment, to evaluate the safety, PK, tolerability and effectiveness of VC004. According to the efficacy, safety and PK of dose-escalation study , the investigator and the sponsor jointly determine the dose for dose extension, and evaluate the anti-tumor effect of VC004 on NTRK fusion-positive subjects, and provide more information for RP2D. According to the tolerability and pharmacokinetic results of dose-escalation study , an appropriate dose or MTD will be selected, namely RP2D, to further assess anti-tumor efficacy and safety in patients with NTRK fusion-positive locally advanced/metastatic solid tumors . ORR will be chosen as the main efficacy indicator to evaluate the anti-tumor efficacy and safety of VC004 .
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
VC004Drug
25 mg capsules,50 mg capsules,100 mg capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety&TolerabilityTime frame: 4 years
- Phase II recommended dose(RP2D)Time frame: 1.5 years
- Maximum tolerated dose(MTD)(If any)Time frame: 1.5 years
- Objective response rate(ORR)Time frame: 4 years
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, China · Recruiting
Liaoning Cancer Hospital & Institute
Shenyang, China · Recruiting
Tianjin Cancer Hospital
Tianjin, China · Recruiting
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China · Recruiting
Hubei Cancer Hospital
Wuhan, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China · Not yet recruiting
Hainan Cancer Hospital
Haikou, Hainan, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Harbin Medical Univercity Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.